BridgeBio Pharma BBIO Share Buybacks
Share Buybacks at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's share buybacks.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's share buybacks?
- BridgeBio Pharma (BBIO) reported share buybacks of $82.5M in Q1 2026.
- How has BridgeBio Pharma's share buybacks changed year-over-year?
- BridgeBio Pharma's share buybacks increased by 70.9% year-over-year, from $48.28M to $82.5M.
- What is the long-term trend for BridgeBio Pharma's share buybacks?
- Over 3 years (2021 to 2024), BridgeBio Pharma's share buybacks has grown at a -100.0% compound annual growth rate (CAGR), from $200M to $0.
- What does share buybacks mean?
- Cash spent by the company to buy back its own shares.
- How do you interpret share buybacks?
- An increase suggests management believes the stock is undervalued or wants to return capital, while a decrease may signal a need to preserve cash for operations.
- How does share buybacks compare across companies?
- Common in mature companies; less frequent in early-stage biotech firms focused on R&D.